{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:43:17Z","timestamp":1791499397108,"version":"4.3.4"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Med Paediatr Oncol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijmpo.ijmpo_43_17","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T06:30:30Z","timestamp":1512628230000},"page":"508","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of ibrutinib in indian patients with relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma: Cases from a named patient program"],"prefix":"10.1055","volume":"38","author":[{"given":"MohanB","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash","family":"Chezhian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryaprakash","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Nagrale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","reference":[{"key":"key-10.4103\/0971-5851.220157-1","first-page":"27","volume-title":"Small B-cell neoplasms with typical mantle cell lymphoma immunophenotypes often include chronic lymphocytic leukemias","author":"Ho","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"key-10.4103\/0971-5851.220157-2","first-page":"vi50","volume-title":"Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Eichhorst","year":"2011","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0971-5851.220157-3","first-page":"405","volume-title":"Guidelines for the investigation and management of mantle cell lymphoma","author":"McKay","year":"2012","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0971-5851.220157-4","first-page":"81","volume-title":"What do we do with chronic lymphocytic leukemia with 17p deletion?","author":"Sellner","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"key-10.4103\/0971-5851.220157-5","first-page":"110","volume-title":"Composite mantle cell lymphoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: A clinicopathologic and molecular study","author":"Hoeller","year":"2013","journal-title":"Hum Pathol"},{"key":"key-10.4103\/0971-5851.220157-6","first-page":"511","volume-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0971-5851.220157-7","first-page":"649","volume-title":"BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity","author":"Cheng","year":"2014","journal-title":"Leukemia"},{"key":"key-10.4103\/0971-5851.220157-8","first-page":"3416","volume-title":"Molecular pathogenesis of mantle cell lymphoma","author":"Jares","year":"2012","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0971-5851.220157-9","first-page":"303","volume-title":"The promising impact of ibrutinib, a bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies","author":"Bhatt","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/0971-5851.220157-10","first-page":"6287","volume-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0971-5851.220157-11","first-page":"1175","volume-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","author":"Woyach","year":"2012","journal-title":"Blood"},{"key":"key-10.4103\/0971-5851.220157-12","first-page":"355","volume-title":"PCI-32765: A novel bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies","author":"Winer","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"key-10.4103\/0971-5851.220157-13","unstructured":"Imbruvica (Ibrutinib) Capsules: Highlights of Prescribing Information; 2014. Available from: https:\/\/www.imbruvica.com\/prescribing-information. [Last accessed on 2017 Jan 18]."},{"key":"key-10.4103\/0971-5851.220157-14","first-page":"263","volume-title":"Ibrutinib:First global approval","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"key-10.4103\/0971-5851.220157-15","first-page":"743","volume-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the global burden of disease study 2013","author":"Global","year":"2015","journal-title":"Lancet"},{"key":"key-10.4103\/0971-5851.220157-16","first-page":"48","volume-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b\/2 trial","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0971-5851.220157-17","first-page":"507","volume-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0971-5851.220157-18","first-page":"213","volume-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0971-5851.220157-19","first-page":"770","volume-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"key-10.4103\/0971-5851.220157-20","doi-asserted-by":"crossref","unstructured":"Rule S, Dreyling M, Hess G, Auer R, Kahl B, Cavazos N, et al. Overall Survival Outcomes in Patients with Mantle-Cell Lymphoma (MCL) Treated with Ibrutinib in a Pooled Analysis of 370 Patients from 3 International Open-Label Studies. Available from: https:\/\/learningcenter.ehaweb.org\/eha\/2016\/21st\/135194\/simon.rule.overall.survival.outcomes.in.patients.with.mantle-cell.lymphoma.html?f=m3. [Last accessed on 2016 Aug 25].","DOI":"10.1111\/bjh.14870"},{"key":"key-10.4103\/0971-5851.220157-21","unstructured":"Hillmen P, O'Brien SM, Byrd JC, Coutre S, Brown JR, Barr PM, et al. Outcomes with single-agent ibrutinib by prior line of therapy and following ibrutinib discontinuation in patients with cll: analyses from phase 3 studies. Available from: https:\/\/learningcenter.ehaweb.org\/eha\/2016\/21st\/133484\/peter.hillmen.outcomes.with.single-agent.ibrutinib.by.prior.line.of.therapy.html?f=m3e968. [Last accessed on 2016 Aug 25]."},{"key":"key-10.4103\/0971-5851.220157-22","first-page":"2425","volume-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0971-5851.220157-23","first-page":"4","volume-title":"Early access programs: Benefits, challenges, and key considerations for successful implementation","author":"Patil","year":"2016","journal-title":"Perspect Clin Res","ISSN":"https:\/\/id.crossref.org\/issn\/2229-3485","issn-type":"print"},{"key":"key-10.4103\/0971-5851.220157-24","first-page":"5446","volume-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia Updating the National Cancer Institute-Working Group 1996 guidelines","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0971-5851.220157-25","first-page":"579","volume-title":"Revised response criteria for malignant lymphoma","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0971-5851.220157-26","unstructured":"National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE); Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010). 2010. Available from: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. [Last accessed on 2016 Aug 18]."},{"key":"key-10.4103\/0971-5851.220157-27","first-page":"2497","volume-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"key-10.4103\/0971-5851.220157-28","first-page":"169","volume-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0971-5851.220157-29","first-page":"769","volume-title":"Ibrutinib: A review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia","author":"Kim","year":"2015","journal-title":"Drugs"},{"key":"key-10.4103\/0971-5851.220157-30","first-page":"3586","volume-title":"FDA approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","author":"de","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0971-5851.220157-31","first-page":"32","volume-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0971-5851.220157-32","first-page":"1573","volume-title":"Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program.A study from the swedish chronic lymphocytic leukemia group","author":"Winqvist","year":"2016","journal-title":"Haematologica"},{"key":"key-10.4103\/0971-5851.220157-33","first-page":"1090","volume-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0971-5851.220157-34","first-page":"1365","volume-title":"Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center","author":"Stephens","year":"2014","journal-title":"Leukemia"},{"key":"key-10.4103\/0971-5851.220157-35","first-page":"1288","volume-title":"Real world data on primary treatment for mantle cell lymphoma: A Nordic lymphoma group observational study","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"key-10.4103\/0971-5851.220157-36","first-page":"1570","volume-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry","author":"Ellin","year":"2014","journal-title":"Blood"}],"container-title":["Indian Journal of Medical and Paediatric Oncology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T22:03:05Z","timestamp":1613685785000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ijmpo.org\/text.asp?2017\/38\/4\/508\/220157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"alternative-id":["220157"],"URL":"https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_43_17","relation":{},"ISSN":["0971-5851"],"issn-type":[{"value":"0971-5851","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}